Sweden

Dela

Välj datumintervall -
Taggar ( valda)

Redeye: Xspray Pharma - Catalysts coming

Although the corona crisis has delayed Xspray’s clinical trials, a review of this significantly de-risked case leads us to raise estimates and fair value. With key catalysts due this year, we highlight the overlooked stock’s undemanding valuation – which puts HyNap-Dasa’s chance of reaching the market at just 30%, versus our 80% – and clear upside potential. Read more and download the research update: https://bit.ly/2KfT67m Start following Xspray Pharma at Redeye to instantly receive our latest analyst updates and comments. This is a press release from Redeye - Research Powered

Redeye: Xspray Pharma - Shaping up to an exciting year

In this update we look at the year ahead with the manufacturing and preparations to take HyNap-Dasa to market. We also update our view regarding the Sprycel, Nexavar and Tasigna market opportunities. We see a strong case in Xspray for the year going forward and reiterate our valuation range with a Base Case of SEK 135.  Read more and download the research update: http://bit.ly/2JnJji9 Start following Xspray Pharma at Redeye to instantly receive our latest analyst updates and comments. This is a press

Redeye: Xspray Pharma - On the right track

Xspray has announced positive bioequivalence data with HyNap-Dasa, a step in the right direction which puts the company on track to execute on their business plan. We see the news as positive and indicative of news to come. With this report, we raise our Base Case to SEK 135 (120) per share. Our Bull and Bear Case remains at SEK 220 and 25 per share, respectively. Read more and download the research report by Mathias Spinnars: http://bit.ly/2CQMVWq  Start following Xspray Pharma at Redeye to instantly receive our latest analyst updates and comments. This is a press release from

Redeye: Initiating coverage of Xspray Pharma

Redeye initiates analyst coverage of Xspray Pharma, a Swedish biopharma with a unique business model. Three product candidates are lined up to reach the market between 2020-2023, and it is our belief that Xspray can utilize their RightSize technology platform to become a niche generic player that can out-maneuver other market players.  Fair value in our Base Case indicates about 80% upside from current share price. Read more and download the research report by Mathias Spinnars: https://goo.gl/TSPBjk Start following Xspray Pharma at Redeye to instantly receive our latest analyst

Det finns inga träffar som matchar nuvarande filter
Det finns inga fler träffar som matchar nuvarande filter
Tillbaka till sidans topp